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INTRODUCTION 
Since the limulus test, a method for the evaluation of 
endotoxin levels using extract from horsehoe crabs (limu- 
lus, spp), was developed in the year 1969 by Levin and 
Bang, there have been reports on endotoxin from portal 
blood without negative gram bacterial infection,1,2 a con- 
dition known as endogenous endotoxemia.3 
Up to now, endogenous endotoxemia in patients with  
liver cirrhosis (LC) is still controversial. This can be seen  
from the great variation in the prevalence of endotoxemia  
in peripheral vein in patients with liver cirrhosis, ranging  
from 0 to 80%.4 The main cause for this difference is  
the methodological factor, reflecting a difference in ex- 
amination technique. Most studies conducted without a  
specific method demonstrate endotoxemia in patients  
with liver cirrhosis.4,5,6,7,8,9,10,11 While studies using a sen- 
sitive method of evaluation for endotoxin found the op- 
posite, detecting no increase in endotoxin in patients with  
liver cirrhosis.12,13 
 
ENDOTOXIN 
Endotoxin is the outer most layer of gram negative  
microorganism, also known as Lipopolysaccharide (LPS). 
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Membrane Proteins 
Endotoxin is made up of the following 3 structures: 
1.  Polysaccharide consisting of specific O chains  
2.  A middle polysaccharide layer divided into inner and  
 outer layers 
3.  Lipid A layer 
All negative gram microorganisms have a similar  
middle structure and Lipid A layer, but differ in the spe- 
cific O polysaccharide chains. Lipid A layer is an impor- 
tant layer in endo-toxicity and is responsible for multiple  
organ failure due to various pathophysiologic responses  
induced during negative-gram sepsis. Lipid A molecules  
with the strongest toxicity are those with 6 fatty acid  
chains, while those having only 1 or 2 fatty acids have  
weak toxicity.14,15 
The lipid A portion of endotoxin is implanted within  
the cell membrane. In order to be effective, endotoxins  
must be released from the bacterial surface. Endotoxins  
are released from the cell wall during bacterial multipli- 
cation as well as when bacteria is destroyed by antibiot- 
ics or complement. Released endotoxins do not directly  
destroy host cells or cause an immediate response, but  
instead do so indirectly through mediators released by  
the host cell itself.14,16,17 
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Inner Bacterial Membrane  
Figure 1. Structure of negative gram bacteria.15 
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Figure 2. Lipopolysaccharide structure15 
 
CELL RESPONSE TO ENDOTOXIN 
The body response towards endotoxin is very com- 
plex. It involves interaction between endotoxin, serum  
components that might strengthen or inhibit endotoxin  
action, and receptors on the surface of specific cells.15  
 Free endotoxins within the blood circulation would  
quickly bind to form complexes with various proteins and  
lipids, including with its specific carrier, the LPS binding 
 
LIPOPOLYSACCHARIDE 
(LPS) 
 
 
 
 
LIPOPOLYSACCHARIDE 
BINDING PROTEIN (LBP) 
protein (LBP). LBP concentration increases within the 
body’s circulation as a response towards inflammatory  
stimuli. These LPS-LBP complexes have strong affinity  
towards CD14 receptors, especially those on the sur- 
face of monocytes and macrophages, including Kupffer 
cells. CD14 is a protein that binds with 55-kDa 
glycophosphatidil (GPI).15,18 
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Figure 3. Macrophage activation by LPS mediated by CD14.14  
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There are three pathways to activate macrophages
and monocytes to release mediators due to stimuli from
endotoxin. The first pathway is where endotoxins bind
with LBP in the body’s circulation. These complexes
then activate CD14 receptors, which instruct macroph-
ages to release mediators. In the second pathway, LPS-
LBP-CD14 complexes are the only factors that allow
endotoxins to interact with other receptors, which stimu-
late macrophages separately or together. The third path-
way is where endotoxins directly activate macrophages
without assistance from LBP or CD14.14
Figure 4. LPS effect on monocytes/macrophages.14
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Macrophages/monocytes including Kupffer cells and
endothelial cells activated by endotoxins release alpha
tumor necrosis factors (alpha-TNF), interleukin 1 (IL-
1), interleukin 6 (IL-6), interleukin 8 (IL-8) and platelet
activating factor (PAF). After these mediators are re-
leased, arachidonic acid is metabolized into leukotrienes,
thromboxane A2 and prostaglandins (especially prostag-
landin E 2 – PGE2) and prostaglandin I 2 (PGI-2). IL-
1and IL-6 activate T cells into producing gamma inter-
feron, interleukin 2 (IL-2), interleukin 4 (IL-4), and granu-
locyte-monocyte colony-stimulating factor (GM-CSF).
All these substances have direct effect on vascular
endothel.19
Alpha TNF plays a role in various aspects of the in-
flammatory response, including induction of inflamma-
tory cytokines (IL-8). Alpha TNF also induces changes
in the vascular wall, activates monocytes and
neutrophilles, and destroys infected cells. Alpha TNF is
also the chief mediator in septic shock. This cytokine
also influences lipid metabolism and storage, causing
cachexia.20
These days, IL-1 is known as an endogenous pyro-
gen. If IL-1 is administered to humans, hypothalamic
effects in the form of rigor, chills, fever, and malaise
ensue. Administration of high doses of IL-1induces hy-
potension. Aside from stimulating acute phase reactions,
IL-1 could also cause leukocytosis and changes in the
plasma protein.20
IL-6 is a hepatocyte-stimulating factor. IL-6 enhances
the secretion of immunoglobulines, increasing the levels
of liver acute phase proteins up to 100 times, but reduc-
ing albumin synthesis up to 50%.20
Tilg H, et al in their study demonstrated increased
levels of proinflammatory cytokines (alpha TNF, IL-1
beta, IL-6), as well as significant increases in gamma-
IFN, in patients with chronic liver disease, changes of
which do not depend on the primary liver disease.21
Kakumu, et al also demonstrated increased produc-
tions of IL-6 in primary billiary liver cirrhosis compared
to control subjects. However, the increase was not sta-
tistically significant.22 In the meantime, Deviere, et al
also found increased alpha TNF and IL-6 levels in pa-
tients with cirrhosis due to alcohol, who were in stable
condition.7
Le Moine, et al, compared alpha TNF levels in nor-
mal control subjects to patients with liver cirrhosis Child
A, B, or C. There was a significant increase in the alpha
TNF levels in patients with liver cirrhosis compared to
normal control subjects, but no significant difference in
alpha-TNF levels among Child A, B, and C patients was
identified.23
The coagulation cascade and complement system are
also activated, even though it is still unclear whether it is
caused directly by endotoxin, stimulated by alpha-TNF,
or other mediators or a combination of either. The comple-
ment system is activated through alternative pathways.
Under normal conditions, complement components are
inactive. During complement reaction, each component
is activated serially, creating a cascade of reactions.
Complement activation could induce cell destruction, in-
flammation and immunological effects.20
Complement influences chemotaxis, anaphylaxis,
vasodilatation, and cytokines. C3a and C5a are
anaphylatoxins that cause mast cell degranulation. Mast
cell degranulation causes the release of histamine and
other mediators that in turn cause vasodilatation. C5a
induces TNF and IL-1 release increases inflammatory
response. Most complements are synthesized by hepa-
tocytes, although mononuclear cells, endothel, fibroblasts,
and epithelial cells of the gastrointestinal tract and uri-
nary tract could also synthesize complement. Liver cir-
rhosis and other chronic liver diseases could cause ab-
normalities such as decreased complement synthesis.20
Activation of XII factors (Hageman factor) and pro-
duction of tissue factors due to stimulation of macroph-
age and endothelial cells by endotoxin could induce dis-
seminated intravascular coagulation (DIC). In addition,
alpha-TNF is suspected to be able to stimulate the de-
velopment of DIC.24
Increased nitric oxide (NO) levels are also found in
endotoxemia. This is becaue the production of inducible
NO-synthase (iNOS) from macrophages, neutrophils,
alpha-TNF, and IL-1 is also increased. Increased NO
levels create a hyperdynamic circulation and peripheral
vasodilatation.25,26
If the above condition and endothelial destruction
continues, organ failure. occurs Endothelial destruction
continues and finally causes hypotension (septic shock).
Aside from the process mentioned above, hypotension
is thought to occur due to direct effect of endotoxins,
cytokines such as alpha-TNF, IL-1, and myocardial de-
pressant substances, on myocardiac muscles, causing
depression of muscle cells.27
Counter-regulatory mechanisms to limit endotoxin
activity
LPS forms a complex with serum lipoproteins, in-
cluding low density lipoproteins (LDLs), high density li-
poproteins (HDLs), and apolipoprotein A, which reduces
toxicity. The LPS complex would then be eliminated from
the body circulation. LBP binds free endotoxin or re-
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leases endotoxins from lypopolisaccharide complexes to
be brought to sCD14 or mCD14. Within serum, we also
find anti-LPS antibodies that act as buffers towards bio-
logical effects of endotoxin. Neutrophil also has specific
anti-LPS activity. Proteins that neutralize LPS, such as
bactericidal/permeability-increasing protein (BPI) and
neutrophil enzymes such as acyloxyacylhydrolase, are
released during phagocytosis. A balance between these
contradictory factors determine the development of sep-
sis and shock.15
It turns out that endotoxin also stimulates the produc-
tion of the anti-inflammatory cytokines IL-10 and IL-4,
which increases significantly up to 28 times and 3 times
normal levels.18 IL-10 acts to protect the liver from de-
struction by alpha-TNF, as well as inhibit the synthesis
of alpha TNF and IL-1-beta.
Endotoxin cleansing mechanism
Mimura, et al studied biliary excretion of endotoxin
using endotoxin labeled with flourescin isothiocyanate
(FITC), demonstrating that after intravenous injection,
FITC-LPS was detected in macrophages in the spleen,
pulmonary dust cells, and on Kupffer cells. Hepatocytes
were also proven to play the same role as Kupffer cells
in processing endotoxins from circulation, and then se-
creting it into the bile. The remaining endotoxin would
then be eliminated by phagocytic cells such as granulo-
cytes, monocytes, and macrophages.28
Tolerance mechanism towards endotoxin
Jarvelainen et al studied the effect of chronic admin-
istration of endotoxin and ethanol on liver pathology and
cytokine of rats, demonstrating that chronic administra-
tion of endotoxin did not result in steatosis, focal inflam-
mation or necrosis of liver cells, even though there were
high levels of endotoxin within the bloodstream. This dem-
onstrates the development of a condition of tolerance
towards high levels of endotoxin circulating for long pe-
riods of time. The mechanism for the development of
such tolerance is still unclear. The absence of liver de-
struction may be due to the presence of anti-inflamma-
tory cytokines IL-10 and IL-4.18
METHOD FOR ENDOTOXIN EVALUATION
Studies to measure plasma endotoxin levels that have
been conducted up to date use two methods of the limu-
lus test. The first method to be used is the kinetic turbi-
dimetry method, which evaluates plasma gel-clot for-
mation after interaction with amebocyte lyzate. Evalua-
tion is determined based on visual observation alone, and
is considered positive if a persistent solid sediment is
found when the tube is placed horizontally.29,30,31 Evalu-
ation using this method produces inconsistent results, due
to a variation of the preparation and sensitivity of the
lyzate used, the method used to prepare plasma samples,
patient population, and statistical analysis.32,33
In the year 1978, Iwanaga et al developed a quanti-
tative method for the evaluation of endotoxin, using syn-
thetic chromogenic peptides as substrates for endotoxin-
sensitive limulus enzymes. This evaluation provides quan-
titative evaluation with a higher specificity and sensitiv-
ity compared to the previous gelation evaluation method.6
Evaluation using the kinetic turbidimetry method that
had become unpopular along with the development of
the chromogenic method, regained popularity in 1985,
when Oishi, et al invented the toxinometer, which com-
puterized turbidity level reading, thus creating a more
standardized and sensitive method.34
Factors within the plasma that influence the limulus
test, including inhibitors and non-specific amydase, must
be eliminated prior to testing. For this cause, several
methods can be used, such as dilution and heating, as
used in the kinetic turbidimetry method. With the chro-
mogenic method, the perchloric acid (PCA) or new-PCA
is used.35
In the meantime, it becomes clearer that the speci-
ficity of limulus examination for the detection of endot-
oxin is inadequate.32,33,36 It has been proven that extracts
coming from the blood of limulus polyphemus (horshoe
crabs) used in the conventional limulus test as well as
the synthetic chromogenic test, also produces a positive
result through another pathway, activated by 1-3-beta-
d-glucan (beta-glucan), a component of fungal cell walls.
Thus, other than the known B and C factors activated
by endotoxin, there seems to be another factor, the G
factor, activated by beta-glucan and beta-glucan-like
activity (BGLA).13,36,37
Lately, many methods have been found to obtain a
lyzate specific only to endotoxin, by eliminating the G
factor from the lyzate. Specificity towards the endot-
oxin is acquired by adding excessive amounts of glucan
into the amebocyte lyzate. Such addition would prevent
activation of the G factor, making the test more specific
for endotoxins.37
Up to now, there are two specific methods for the
evaluation of endotoxin. The first method is the calori-
metric limulus test (endospecy) method. In this test, a
synthetic substance is added as a clotting enzyme.
Paranitroalanine (pNA) is released from the enzyme
substrate, changing the pNA into red azodyes by means
of diazocoupling. The content of the red azodye is then
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measured using photometry at 550 nm. The endotoxin is
then determined using a standard curve.37
The second method is the kinetic turbidimetry method.
This method requires the use of computers, but the pro-
cedure is fairly simple. The principle of the instrument is
as follows: if an endotoxin-containing sample is mixed
with limulus reagents, a gellatinous sediment is formed.
The passage of light would then be reduced. A reduc-
tion up to the pre-programmed cut-off value is then cal-
culated using the instrument. The percent of light trans-
mittance to reach the cut-off value is called the gel sedi-
mentation time or gelation time. Endotoxin could then be
quantitatively determined as log [log(Tg)]. If Tg of the
sample to be measured has been determined, the level
of endotoxin could be calculated using the standard
curve.38
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Figure 5. The principle of limulus evaluation
THE PATHOPHYSIOLOGY OF ENDOGENOUS
ENDOTOXEMIA
Endogenous endotoxemia is a condition where en-
dotoxins are found within the circulation unaccompanied
by negative gram bacteremia.39 The intestinal mucosal
barrier in normal mammals allow the possibility of a small
number of macromolecules to pass through the mucosa
of the small intestines. This has been demonstrated in
laboratory animals, where a small number of endotoxin
from the intestinal mucosa normally passes through the
normal mucosa into the portal blood vein.39,40 In condi-
tions of bowel inflammation, alcoholism, hypoperfusion,
or anoxia, liver cirrhosis and extrahepatic obstruction,
there is a significant increase of endotoxin absorption
through the intestinal wall.3,41
Endogenous endotoxemia should be differentiated
from bacterial translocation. Bacterial translocation is a
condition where live bacteria from the gastrointestinal
tract passes through the epithelial mucosa to infect me-
senteric lymph nodes (MLNs) and systemic organs.42
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Figure 6. The schematic relationship between liver,
spleen, and bowel
Several reports state that endogenous endotoxemia
is closely related with disorders that reduce liver func-
tion,2 and intestinal wall,13 trauma,42 and reduced immune
system.13 The concept of endogenous endotoxemia has
become widely accepted.
The presence of a portosystemic shunt and reduced
phagocytic function of the rethiculoendothelial system
are important factors for the development of endotoxemia
in patients chronic liver disease.4 Liver is the main plase
for the cleansing of endotoxin performed by Kupffer cells.
In liver cirrhosis, there is reduced Kupffer cell function,r
esulting in inadequate detoxification of endotoxins.
Portosystemic shunting also results in the passage of
endotoxin directly into the systemic circulation. Other
factors that contribute to the high level of endotoxin in
alcoholic liver disease is increased permeability of the
intestinal mucosa towards macromolecules. Such in-
crease in permeability facilitates the passage of endot-
oxin from the gastrointestinal tract.4 In addition to the
points mentioned, there is also bacterial overgrowth in
the small intestines of patients with liver cirrhosis, par-
ticularly due to alcoholism. Such bacterial overgrowth
increases endotoxin production in the gastrointestinal
tract.
Takinawa et al demonstrated a significant increase
of endotoxin absorption in laboratory rats injected with
lypopolisaccharide (LPS) in the colon. This is found in
rats with liver cirrhosis, alcoholism, and extra-hepatic
obstruction. Through the electron microscope, endotoxin
particles were observed to pass through the colon epi-
thelial cell.
Liver cirrhosis
Reduce Kupffer cells and hepatocyte functio
Portosystemic shunt
Increased intestinal permeaility
Bacterial over growth
Endogenous endotoxemia
Figure 7. Factors that play a role in the development of
endogenous endotoxemia
Endogenous endotoxemia in liver cirrhosis
In the year 1972, Caridis et al reported two cases of
liver cirrhosis accompanied by increased levels of en-
dotoxin, detected using the limulus test, without bacter-
emia.43 This was the first report on endogenous
endotoxemia. In the year 1976, Wilkinson et al reported
45 cases of cirrhosis where endotoxemia was detected
in 84% (21/25) patients accompanied by renal failure,
and in only 10% (2/20) of endotoxemia in patients with-
out renal failure.30 Clemente et al  also reported 43 cases
of liver cirrhosis with ascites where endotoxemia was
detected in 41% (8/22) of patients with renal failure, while
endotoxemia was not detected patients without renal
failure (0/21).31 On another occasion Tarao et al reported
that out of 29 patients with liver cirrhosis and ascites, 23
(80%) were found with endotoxin in their ascites fluid,
while 22 (76%) was positive for endotoxin within the
plasma.29 Only 23% (4/17) were positive among those
without ascites.29 Among the many studies that found
endotoxemia in patients with liver cirrhosis, Fulenwider
et al found the opposite, and reported no endotoxin in the
peripheral vein, portal vein, nor the ascites fluid of 38
study subjects with liver cirrhosis.44 All of the studies
mentioned utilized the conventional limulus amebocyte
lysate (LAL) test which is considered positive if gel for-
mation is visually observed.
Lumsden et al used the non-specific chromogenic
method to study the incidence of endotoxemia in the
portal vein, hepatic vein, and peripheral vein in patients
with liver cirrhosis. They found the highest levels of en-
dotoxin in the portal vein, hepatic vein, and peripheral
vein, respectively.6
Lin et al, using the same method as Lumsden, et al,
demonstrated that the level of plasma endotoxin in-
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Volume 2, Number 3, December 2001 19
Andri Sanityoso Sulaiman: Endogenous Endotoxemia in Patients with Liver Cirrhosis
creased progressively according to the severity of liver
dysfunction.10 Fukui et al (1991), in comparing the en-
dotoxin levels of patients with  liver cirrhosis due to al-
coholism and non-alcoholic liver cirrhosis patients, found
a higher level of endotoxin in patients with liver cirrhosis
due to alcoholism.4 Even though there have been many
data that demonstrated increased endotoxin levels in liver
cirrhosis using the synthetic chromogenic method, Le
Moine et al did not identify such increase in patients with
liver cirrhosis classified as Child-Pugh A, B, and C in
the 49 study subjects.23
In two other studies using the endospecy instrument
(an endotoxin-sensitive chromogenic method), Fukui et
al conducted measurement of endotoxin levels in patients
with chronic hepatitis and liver cirrhosis in patients with
liver cirrhosis and bleeding from esophageal varices.
Increased endotoxin levels were found in accordance
with the progressiveness of liver disease and there is an
increase in patients with liver cirrhosis and variceal bleed-
ing compared to those without.45,46 Results of the study
by Fukui is not supported by other studies using the same
method. In the study, Fukui modified the standard curve
calculation to produce a positive result.
Yajima et al in a study on 8 patients with liver cirrho-
sis complicated by disseminated intravascular coagula-
tion (DIC) conducted endotoxin evaluation using the
convensional method and the endospecy method, dem-
onstrating positive results by conventional evaluation
while no increased levels of endotoxin was not detected
using the endotoxin-sensitive endospecy. This finding was
supported by Kikuchi et al, that studied 9 patients with
liver cirrhosis and esophageal varices undergoing the
esophageal operation transaction operation and splenec-
tomy, finding no increase in endotoxin levels either in the
portal vein or the peripheral vein using the endospecy
method.
There is still the possibility that the endotoxin was not
detected using a specific method because the endotoxin
binds with various proteins and undergo changes within
the body, even though this hypothesis has not been proven
and may not be correct, recalling the difference between
the specific and non-specific method lies only on the G
factor, while the other principles of evaluation is the same.
Why endotoxemia does not occur in liver cirrhosis
The presence of endogenous endotoxemia in liver
cirrhosis theoretically poses a serious condition, since
the endotoxin would activate macrophages/monocytes
to release mediators that would then stimulate the in-
flammatory cascade, resulting in sepsis and septi shock.
This is rarely found, except in patients with negative-
gram infection.
Gabe et al demonstrated that patients with end-stage
chronic liver disease (liver cirrhosis with portal hyper-
tension) has a normal intestinal permeability, preventing
excessive passage of endotoxin through the intestinal
mucosal barrier.47 However, there has been many stud-
ies that demonstrated otherwise, identifying increased
intestinal permeability. Studies on Kupffer cell function
in patients with liver cirrhosis also found contradictory
results, some stating reduced Kupffer cell function and
some stating that Kupffer cell function was still adequate
despite liver cirrhosis.
CONCLUSION
Evaluations of endotoxin levels that have been con-
ducted up to now have produced controversial results,
with studies using the conventional method mostly pro-
ducing positive results. Further evaluation using the spe-
cific method did not detect increased endotoxin levels in
stable liver cirrhosis patients. Such finding produces the
believe that there is another substance that produces a
positive result in the conventional limulus test.
These new findings cast a doubt on the current as-
sumption of the concept of endogenous endotoxemia in
patients with liver cirrhosis. There needs to be a reevalu-
ation to explain a more precise concept of endotoxemia
in patients with liver cirrhosis.
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